Skip to main content

Table 1 Characteristics of the 215 subjects with influenza-related ARDS

From: Risk factors for prolonged mechanical ventilation in critically ill patients with influenza-related acute respiratory distress syndrome

 

All patients

Prolonged mechanical ventilation (PMV)

 

Weaning in PMV

 

Characteristics

 

Yes

No

p Value

Success

Failure

p Value

 

(n = 215)

(n = 78)

(n = 137)

 

(n = 44)

(n = 34)

 

Baseline data

 Age (years)

59.27(± 14.48)

58.22(± 11.74)

59.88(± 15.83)

0.38

59.25(± 12.12)

56.88(± 11.27)

038

 Male sex

134(62.3%)

50(64.1%)

84(61.3%)

0.69

31(70.5%)

19(55.9%)

0.18

 Body mass index BMI (kg/m2)

25.67(± 5.78)

26.84(± 4.77)

25.53(± 5.70)

0.087

26.65(± 4.19)

27.09(± 5.48)

0.68

 BMI > 25 (kg/m2)

124(57.7%)

56(71.8%)

68(49.6%)**

0.002

23(67.6%)

33(75%)

0.47

 Malignancy

26(12.1%)

12(15.4%)

14(10.2%)

0.26

7(15.9%)

5(14.7%)

0.88

 Type II diabetes mellitus

63(29.3%)

22(28.2%)

41(29.9%)

0.79

11 (25%)

11(32.4%)

0.47

 Cerebrovascular disease

14(6.5%)

4(5.1%)

10(7.3%)

0.54

4

0

0.13

 Liver disease

22(10.2%)

9(11.5%)

13(9.5%)

0.63

4(11.8%)

5(11.4%)

1.0

 Cardiac disease

25(11.6%)

5(6.4%)

20(14.6%)

0.072

3(8.8%)

2(4.5%)

0.65

 Hypertension

93(43.3%)

35(44.9%)

58(42.3%)

0.72

19(43.2%)

16(47.1%)

0.73

 Immunosuppressantb use before influenza infection

10(4.7%)

5(6.4%)

5(3.6%)

0.5

1(2.3%)

3(8.8%)

0.31

 Autoimmune disease

14(6.5%)

6(7.7%)

8(5.8%)

0.60

2(4.5%)

4(11.8%)

0.40

 End-stage renal disease

14(6.5%)

7(9.0%)

7(5.1%)

0.27

4(9.1%)

3(8.8%)

1.0

Severity scores

 APACHE II score

22.59(± 8.13)

24.14(± 8.52)

21.7(± 7.8)*

0.034

23.30 ± 8.74

25.24(± 8.23)

0.32

ARDS a Severity

   

0.18

  

0.76

 Severe

122(56.7%)

49(62.8%)

73(53.3%)

 

27(61.4%)

22(64.7%)

 

 Mild to moderate

93(43.3%)

29(37.2%)

64(46.7%)

 

17(38.6%)

12(35.3%)

 

Treatments and clinical outcome

 Prone

49(22.8%)

23(29.5%)

26(19%)

0.08

14(31.8%)

9(26.5%)

0.61

 ECMO

34(15.8%)

26(33.3%)

8(5.8%)**

 < 0.01

8(18.2%)

18(52.9%)**

 < 0.01

 Combined with bacterial pneumonia onset before D21

67(31.2%)

39(50%)

28(20.4%)**

 < 0.01

26(59.1%)

22(64.7%)

0.61

 Bacteremia onset before D21

34(15.8%)

19(24.4%)

15(10.9%)**

0.01

6(13.6%)

13(38.2%)*

0.012

 Steroid user

127(59.1%)

46(59%)

81(59.1%)

0.98

23(52.3%)

23(67.6%)

0.17

 Sedation

159(74%)

60(76.9%)

99(72.3%)

0.45

32(72.7%)

28(82.4%)

0.32

 Neuromuscular blockade > 48 h

119(55.3%)

59(75.6%)

60(43.8%)***

 < 0.001

32(72.7%)

27(79.4%)

0.5

 Need for vasopressor agents

103(47.9%)

49(62.8%)

54(39.4%)***

 < 0.01

25(56.8%)

24(70.6%)

0.21

 Renal replacement therapy c

19(8.8%)

11(14.1%)

8(5.8%)*

0.04

6(13.6%)

5(14.7%)

1.0

 Ventilator-duration (days)

21.18(± 17.74)

39.24(± 17.77)

10.90(± 4.77)***

 < 0.001

36.12(± 14.60)

43.29(± 20.72)

0.09

 ICU stay (days)

22.32(± 18)

38.18(± 20.65)

13.22(± 6.24)***

 < 0.001

36(± 19.22)

41(± 22.34)

0.29

 Hospital-stay (days)

37.59(± 27.38)

54.12(± 32.73)

28.11(± 18)***

 < 0.001

58.90(± 29.70)

47.92(± 35.77)

0.14

 In hospital Mortality

42(19.5%)

31(39.7%)

11(8%)***

 < 0.001

5(11.4%)

26(76.5%)***

 < 0.001

  1. Data are presented as the mean ± standard deviation and number (%)
  2. APACHE II Acute Physiology and Chronic Health Evaluation, ARDS acute respiratory distress syndrome, ECMO extracorporeal membrane oxygenation
  3. aIn accordance with Berlin definition
  4. bOral prednisolone equivalent dosage > 5 mg/day or > 150 mg cumulative dose within 1 month before influenza infection; or regular treatment using other immunosuppressants within 1month before influenza infection
  5. cExcluding those with end-stage renal disease receiving regular hemodialysis
  6. *< 0.05
  7. **0 < 0.01
  8. ***0 < 0.001
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us